Tasonermin (Beromun®; developed by Boehringer Ingelheim), an agent approved for use by the European Medicine Agency (EMA) in 1999, is a human recombinant form of soluble TNF-α produced in Escherichia coli cell culture that can kill cancer cells directly, destroy the blood vessels that supply tumors with nutrients and oxygen, and activate the immune system to fight tumor vascular structure (Figure 7A). Here, TNF is linked to cancer.